Latest Caphosol Stories
Invado Pharmaceuticals announced the completion of a pilot study for NeutraSal® (supersaturated calcium phosphate rinse) in patients experiencing medication-induced xerostomia or dry mouth.
A NASA technology originally developed for plant growth experiments on space shuttle missions has successfully reduced the painful side effects resulting from chemotherapy and radiation treatment in bone marrow and stem cell transplant patients.
Treatment is being developed to reduce oral infection and pain associated with cancer treatments Honolulu, HI and Claremont CA (PRWEB) March 22, 2011 Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgenâ€™s proprietary oral disease treatments.
KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
DALLAS and NEW YORK, Feb. 9, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
KALAMAZOO, Mich., Nov. 11, 2010 /PRNewswire/ -- NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study.
DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc.
DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
DALLAS and NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com.
DALLAS, and NEW YORK, Sept. 14 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
- Emitting flashes of light; glittering.